Celgene Corporation (NASDAQ:CELG): According to Barclays, Celgene’s fair value at $74 and thinks shares are supported with a $60 floor. Stifel predicts that Celgene will possess enough data to support a filing both the U.S. and Europe in mid-2013. The firm thinks that SPM safety risk is minimal and anticipates the EU approval of the expanded label to be in 1H 2014 instead of former expectations of Q2 2012. The shares hold a Buy rating and the stock’s price target has fallen from $87 to$84.
FedEx Corporation’s (NYSE:FDX) Q4 EPS exceeded expectations, influencing Argus to maintain its above-consensus FY13 EPS estimate for the company. The firm predicts that the company is positioned to benefit from the improving U.S economy and increasing international demand. The firm maintains a Buy rating on the shares.
Under Armour, Inc. (NYSE:UA): Sterne Agee is optimistic about Under Armour’s new Spine RPM shoe technology. The firm gives the shares a Buy rating.
Bed Bath & Beyond, Inc. (NASDAQ:BBBY): Raymond James defended Bed Bath and Beyond shares.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.